STEGLATRO FILM-COATED TABLETS 15MG

Country: Singapúr

Tungumál: enska

Heimild: HSA (Health Sciences Authority)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
24-11-2021

Virkt innihaldsefni:

Ertugliflozin L-PGA eqv to Ertugliflozin

Fáanlegur frá:

MSD PHARMA (SINGAPORE) PTE. LTD.

ATC númer:

A10BK04

Lyfjaform:

TABLET, FILM COATED

Samsetning:

Ertugliflozin L-PGA eqv to Ertugliflozin 15mg

Stjórnsýsluleið:

ORAL

Gerð lyfseðils:

Prescription Only

Framleitt af:

Pfizer Manufacturing Deutschland GmbH

Leyfisstaða:

ACTIVE

Leyfisdagur:

2020-03-11

Vara einkenni

                                CCDS-MK8835-T-032018
STEGLATRO® Film-coated Tablets 5 mg
STEGLATRO® Film-coated Tablets 15 mg
1.
INDICATIONS AND USAGE
STEGLATRO (ertugliflozin) is indicated as an adjunct to diet and
exercise to improve glycemic control
in adults with type 2 diabetes mellitus
[see 10. CLINICAL STUDIES]
.
2.
DOSAGE AND ADMINISTRATION
2.1
General
The recommended starting dose of STEGLATRO is 5 mg once daily, taken
in the morning, with or
without food. In patients tolerating STEGLATRO 5 mg once daily, the
dose may be increased to
15 mg once daily if additional glycemic control is needed.
In patients with volume depletion, correcting this condition prior to
initiation of STEGLATRO is
recommended
[see 5. WARNINGS AND PRECAUTIONS (5.1)]
.
2.2
Renal Impairment
Assessment of renal function is recommended prior to initiation of
STEGLATRO and periodically
thereafter
[see 5. WARNINGS AND PRECAUTIONS (5.3)]
.
STEGLATRO should not be initiated in patients with an estimated
glomerular filtration rate (eGFR)
less
than
60 mL/min/1.73 m
2
[see
5.
WARNINGS
AND
PRECAUTIONS
(5.3)
and
7.
USE
IN
SPECIFIC POPULATIONS (7.5)]
.
Use of STEGLATRO should be discontinued in patients with an eGFR
persistently between 45 to
<60 mL/min/1.73 m
2
or if eGFR falls below 45 mL/min/1.73 m
2
.
3.
INSTRUCTIONS FOR USE
Not applicable.
4.
CONTRAINDICATIONS
History of a serious hypersensitivity reaction to STEGLATRO.
5.
WARNINGS AND PRECAUTIONS
General
STEGLATRO is not recommended in patients with type 1 diabetes mellitus
or for the treatment of
diabetic ketoacidosis.
5.1
Hypotension
STEGLATRO causes an osmotic diuresis, which may lead to intravascular
volume contraction.
Therefore, symptomatic hypotension may occur after initiating
STEGLATRO
[see 8. ADVERSE
REACTIONS
(8.1)]
,
particularly
in
patients
with
impaired
renal
function
(eGFR
less
than
60 mL/min/1.73 m
2
),
elderly
patients
(≥ 65 years),
or
patients
on
diuretics.
Before
initiating
STEGLATRO, volume status should be assessed and corrected if
indicated. Monitor for signs and
symptoms after initiating therapy
                                
                                Lestu allt skjalið
                                
                            

Leitaðu viðvaranir sem tengjast þessari vöru